E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
keratoconjunctivitis sicca |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10023350 |
E.1.2 | Term | Keratoconjunctivitis sicca |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this study is to evaluate the efficacy of unpreserved Dexamethasone Phosphate 0.1% eye drops versus placebo in patients with bilateral severe keratoconjunctivitis sicca due to primary or secondary Sjögren syndrom. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Male or female aged from 18 to 75 years old. 2.Primary or secondary Sjögren: ØAlready diagnosed by the rheumatologist and the maxillofacial specialist. ØFulfilling the European criteria (Vitali et al 1996) 3.Severe dry eye syndrome in BOTH EYES defined by: -Questioning on patient’s feeling: score ≥ 3. -At least two of the following ocular symptoms suggestive of dry eye: burning, stinging, dryness feeling, sandy and/or gritty sensation, light sensitivity, reflex tearing, ocular fatigue, blurred vision (improved by tears substitute). -Schirmer test < 5 mm in 5 min OR BUT < 7 s. -Keratoconjunctivitis defined by a lissamine green score (Van Bijsterveld score) ≥ 4
|
|
E.4 | Principal exclusion criteria |
1.Dry eye syndrome primarily related to inflammation of ocular surface 2. Contraindications to topic dexamethasone :Glaucoma, IOP steroid responder, Herpes simplex, vaccinia, varicella zoster and most other viral infections of the cornea and conjunctiva, bacterial infections, all lesions with involvement of the corneal epithelium, Tuberculosis, fungal infections, acute purulent infections, which like other diseases caused by micro-organisms, can be masked or aggravated by the presence of steroids 3.Eyelid dysfunction : Eyelid malposition, Blepharospasm, Facial paralysis, Severe ocular progressive rosacea/ severe blepharitis 4.History WITHIN THE LAST 3 MONTHS before the inclusion visit of : Traumatism, Infection (Viral conjunctivitis / Bacterial conjunctivitis / Staphylococcal blepharitis) 5.Any relevant ocular anomaly interfering with ocular surface: chemical burns, corneal distrophy, orbital radiotherapy, etc……. 6.Known history of ocular allergy. 7. Best corrected far visual acuity (VA) ≤ 1/10.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary efficacy criteria: 1.Symptomatology within the last 48 hours: evaluation on a Visual analogue scale (Day 7).
Secondary efficacy criteria:
1.Symptomatology within the last 48 hours: evaluation on a Visual analogue scale (Day 35). 2.Patient’s feeling assessment. 3.Ocular symptoms suggestive of dry eye within the last 48 hours. §Schirmer test without anaesthesia. §Slit lamp examination: After fluorescein administration by a blue light beam: BUT and Oxford scheme. By a white light beam: Blepharitis (including meibomitis), Conjunctival hyperaemia, Conjunctival discharge, Chemosis, Folliculo-papillary conjunctivitis, filamentary keratitis, other clinically relevant signs. After lissamine green administration: Van Bijsterveld score. §Assessments of the efficacy for right and left eye by the investigator. §Number of drop out patients due to lack of efficacy §Change in ocular concomitant artificial tears.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Information not present in EudraCT |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
double masked, intraindividual comparison |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
last phone contact with the last patient |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |